NCT06263738 (CHILL'D) is a NA clinical trial of Whole Body Hyperthermia in Depression, sponsored by Barry Sandler.

Who is sponsoring NCT06263738?

NCT06263738 is sponsored by Barry Sandler.

What drugs are being tested in NCT06263738?

Interventions in NCT06263738: Whole Body Hyperthermia, Cold Water Plunge.

What condition does NCT06263738 study?

NCT06263738 studies Depression, Mood Disorders, Healthy (Controls).

Is NCT06263738 still recruiting?

NCT06263738 is currently recruiting now. Last updated 13 November 2025.

Last reviewed 2025-11-13 · How we verify

NCT06263738: CHILL'D

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cold and Heat Investigation to Lower Levels of Depression

Recruiting now NA Last updated 13 November 2025

What this trial tests

NA trial testing Whole Body Hyperthermia in Depression in 162 participants. Currently enrolling.

Timeline

14 May 2024

Primary endpoint
1 April 2027

1 April 2027

Quick facts

Lead sponsor	Barry Sandler
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	162
Start date	14 May 2024
Primary completion	1 April 2027
Estimated completion	1 April 2027
Sites	1 location across United States

Drugs / interventions tested

Whole Body Hyperthermia
Cold Water Plunge

Conditions studied

Depression — all drugs for Depression →
Mood Disorders — all drugs for Mood Disorders →
Healthy (Controls) — all drugs for Healthy (Controls) →

Sponsor

Barry Sandler

Who can join

Adults 18 to 65, any sex, with Depression or Mood Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will recruit 112 medically healthy adults (aged 18-65) currently experiencing depressive symptoms to be randomized to receive either a single Whole Body Hyperthermia (heat therapy) treatment or a Whole Body Hyperthermia treatment followed by a cold water plunge. Participants will complete a baseline assessment of their depressive symptoms as well as 1-week and 2-week post-treatment followup assessments.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Depression

Currently open trials in the same condition.

NCT07336238 — Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or · Phase 2 · recruiting
NCT06906939 — A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression · EARLY_PHASE1 · recruiting
NCT07517549 — Sexual Health Education During Pregnancy · NA · recruiting
NCT06408246 — ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression · Phase 2 · recruiting
NCT07449676 — Effects of an Innovative TCM-based Tui Jing Therapy on Psychological and Neurophysiological Functions in Depression · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06263738 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Barry Sandler
Last refreshed: 13 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06263738.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing